Role of tumor microenvironment in cancer progression and therapeutic strategy

Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body's immune system. It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death-1 (PD-1), programmed death-1 ligand-1 (PD-L1), and programmed death Ligand-2 (PD-L2), the construction of antigen chimeric T cells (CAR-T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME. Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD-1 and TME, and promising cancer immunotherapy therapeutics.

[1]  Gong Chen,et al.  Kinetic modeling: A tool for temperature shift and feeding optimization in cell culture process development. , 2022, Protein expression and purification.

[2]  A. Korman,et al.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial , 2021, Nature Reviews Drug Discovery.

[3]  Yu-Shang Yang,et al.  Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications , 2021, Frontiers in Oncology.

[4]  H. Mirzaei,et al.  Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors , 2021, Frontiers in Immunology.

[5]  P. Steinberger,et al.  Emerging targets for anticancer vaccination: PD-1 , 2021, ESMO open.

[6]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[7]  Jin Tan,et al.  The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury , 2021, Cell Communication and Signaling.

[8]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2021, The Journal of clinical investigation.

[9]  R. Geiger,et al.  Metabolic modulation of tumours with engineered bacteria for immunotherapy , 2021, Nature.

[10]  L. Zhong,et al.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives , 2021, Signal Transduction and Targeted Therapy.

[11]  P. Papageorgis,et al.  The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities , 2021, Cancers.

[12]  S. Ostrand-Rosenberg.  Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer , 2021, Annual Review of Cancer Biology.

[13]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[14]  C. Chiang,et al.  Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy , 2021, International journal of molecular sciences.

[15]  G. Weinstock,et al.  Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice , 2021, Nature Microbiology.

[16]  Li Duan,et al.  Engineering exosomes for targeted drug delivery , 2021, Theranostics.

[17]  R. Montironi,et al.  Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer , 2021, Cancers.

[18]  D. Banerjee,et al.  Metabolic Interactions Between Tumor and Stromal Cells in the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.

[19]  L. Peirson,et al.  Impact of postal correspondence letters on participation in cancer screening: a rapid review. , 2020, Preventive medicine.

[20]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[21]  S. Lheureux,et al.  Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. , 2020, Future oncology.

[22]  Lanjuan Li,et al.  The Intestinal Microbiota and Colorectal Cancer , 2020, Frontiers in Immunology.

[23]  K. Lukong,et al.  Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects , 2020, Frontiers in Cell and Developmental Biology.

[24]  T. Sasada,et al.  Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy , 2020, Journal of immunology research.

[25]  R. Roden,et al.  PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model , 2020, Cancer Immunology, Immunotherapy.

[26]  Z. Szallasi,et al.  Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage , 2020, Science.

[27]  A. Young,et al.  Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies , 2020, Frontiers in Immunology.

[28]  Jun Yan,et al.  Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. , 2020, Trends in cancer.

[29]  Y. Song,et al.  Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment , 2020, Journal of Hematology & Oncology.

[30]  Xiaojun Zhu,et al.  Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy , 2020, Diagnostic Pathology.

[31]  Sherven Sharma,et al.  PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer , 2020, Vaccines.

[32]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[33]  Chenqi Xu,et al.  Immune checkpoint signaling and cancer immunotherapy , 2020, Cell Research.

[34]  T. Vanden Berghe,et al.  Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer , 2020, Nature Medicine.

[35]  D. Loessner,et al.  3D approaches to model the tumor microenvironment of pancreatic cancer , 2020, Theranostics.

[36]  E. Sahai,et al.  SnapShot: Cancer-Associated Fibroblasts , 2020, Cell.

[37]  M. Zucchetti,et al.  CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy , 2020, Cells.

[38]  James Pannucci,et al.  Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics , 2020, Frontiers in Immunology.

[39]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[40]  A. Mikos,et al.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. , 2020, Tissue engineering. Part B, Reviews.

[41]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[42]  M. Penichet,et al.  Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model , 2020, Oncoimmunology.

[43]  F. Marincola,et al.  The Tumor Microenvironment , 2016, Methods in Molecular Biology.

[44]  J. Aerts,et al.  Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model , 2020, Frontiers in Immunology.

[45]  Yi Zhang,et al.  Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment , 2019, Journal of Hematology & Oncology.

[46]  I. Duarte,et al.  Metabolic crosstalk in the breast cancer microenvironment. , 2019, European journal of cancer.

[47]  Lingxiang Mao,et al.  The role of exosomal PD-L1 in tumor progression and immunotherapy , 2019, Molecular Cancer.

[48]  Jonathan Strutz,et al.  Metabolic kinetic modeling provides insight into complex biological questions, but hurdles remain. , 2019, Current opinion in biotechnology.

[49]  A. Mikos,et al.  Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. , 2019, Acta biomaterialia.

[50]  M. Migden,et al.  Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma , 2019, Expert review of clinical pharmacology.

[51]  J. van Bergen,et al.  A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control , 2019, Oncoimmunology.

[52]  G. Berchem,et al.  Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges , 2019, Cells.

[53]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[54]  L. Sevenich,et al.  Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis , 2019, Front. Immunol..

[55]  Shunfeng Cai,et al.  Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma , 2019, Journal of Immunotherapy for Cancer.

[56]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[57]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[58]  Katarzyna Guzik,et al.  Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles , 2019, Molecules.

[59]  J. Inokuchi,et al.  Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma , 2019, Cancer management and research.

[60]  A. Aref,et al.  Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance , 2019, Molecular Cancer.

[61]  Dihua Yu,et al.  Exosomes in cancer development, metastasis, and immunity. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[62]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[63]  G. Stassi,et al.  Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance , 2019, Molecular Cancer.

[64]  Ryohei Katayama,et al.  Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer , 2019, The Journal of experimental medicine.

[65]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[66]  J. Kochenderfer,et al.  Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. , 2019, Blood reviews.

[67]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[68]  A. R. Fernandes,et al.  Targeting Tumor Microenvironment for Cancer Therapy , 2019, International journal of molecular sciences.

[69]  S. Karam,et al.  Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment , 2019, Front. Immunol..

[70]  Lu Zhang,et al.  Immune targets in the tumor microenvironment treated by radiotherapy , 2019, Theranostics.

[71]  J. Gulley,et al.  Product review: avelumab, an anti-PD-L1 antibody , 2018, Human vaccines & immunotherapeutics.

[72]  Ping-Chih Ho,et al.  Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy. , 2019, Physiological reviews.

[73]  Z. Zeng,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[74]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[75]  L. Paz-Ares,et al.  Durvalumab in NSCLC: latest evidence and clinical potential , 2018, Therapeutic advances in medical oncology.

[76]  R. Soffietti,et al.  STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis , 2018, Nature Medicine.

[77]  Vikram B. Chakravarthy,et al.  Houdini Tumor: Case Report and Literature Review of Pregnancy-Associated Meningioma. , 2018, World neurosurgery.

[78]  A. Möller,et al.  Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment , 2018, PloS one.

[79]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[80]  S. Kopetz,et al.  Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. , 2018, Future oncology.

[81]  R. Joseph,et al.  Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives , 2018, Journal of kidney cancer and VHL.

[82]  J. Taube,et al.  Implications of the tumor immune microenvironment for staging and therapeutics , 2018, Modern Pathology.

[83]  A. Sewell,et al.  CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. , 2018, Blood.

[84]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[85]  R. Deberardinis,et al.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications , 2018, Pigment cell & melanoma research.

[86]  A. Kimmelman,et al.  Metabolic Interactions in the Tumor Microenvironment. , 2017, Trends in cell biology.

[87]  L. Skalniak,et al.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.

[88]  K. Zak,et al.  Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. , 2017, Structure.

[89]  T. Jiang,et al.  Combined Radiotherapy and Anti–PD‐L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[90]  Heather H Gustafson,et al.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics. , 2017, Advanced drug delivery reviews.

[91]  Yangbing Zhao,et al.  Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9 , 2017, Protein & Cell.

[92]  B. Dwarakanath,et al.  Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy , 2017, Front. Oncol..

[93]  I. Scarfò,et al.  Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment , 2017, Journal of Immunotherapy for Cancer.

[94]  Zhiqiang Wu,et al.  New development in CAR-T cell therapy , 2017, Journal of Hematology & Oncology.

[95]  J. Medema,et al.  Intra-tumor heterogeneity from a cancer stem cell perspective , 2017, Molecular Cancer.

[96]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[97]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[98]  Qiang Zhang,et al.  Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment , 2017, Theranostics.

[99]  R. Fietkau,et al.  Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells , 2016, Front. Immunol..

[100]  Antonios G Mikos,et al.  IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. , 2016, Journal of the National Cancer Institute.

[101]  R. Weichselbaum,et al.  The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications , 2016, Science Immunology.

[102]  Yu Sun.  Tumor microenvironment and cancer therapy resistance. , 2016, Cancer letters.

[103]  Simon C Watkins,et al.  The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. , 2016, Immunity.

[104]  J. Goh,et al.  Three‐dimensional spatial configuration of tumour cells confers resistance to chemotherapy independent of drug delivery , 2016, Journal of tissue engineering and regenerative medicine.

[105]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[106]  Bonnie F. Sloane,et al.  Pathomimetic cancer avatars for live-cell imaging of protease activity. , 2016, Biochimie.

[107]  Lin Xu,et al.  PKM2 and cancer: The function of PKM2 beyond glycolysis , 2016, Oncology letters.

[108]  Martin Scherzer,et al.  Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment. , 2015, Seminars in cancer biology.

[109]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[110]  Kevin J. Harrington,et al.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.

[111]  William H. Bisson,et al.  The effect of environmental chemicals on the tumor microenvironment. , 2015, Carcinogenesis.

[112]  M. B. Ahmed,et al.  PD-1 induction through TCR activation is partially regulated by endogenous TGF-β , 2014, Cellular and Molecular Immunology.

[113]  M. Shakibaei,et al.  Curcumin Suppresses Crosstalk between Colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of EMT , 2014, PloS one.

[114]  B. Vanderhyden,et al.  Consideration of GREB1 as a potential therapeutic target for hormone-responsive or endocrine-resistant cancers , 2014, Expert opinion on therapeutic targets.

[115]  N. Itano,et al.  Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.

[116]  C. Oliver,et al.  Mast Cell Function , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[117]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[118]  S. Ambs,et al.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.

[119]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[120]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[121]  Y. Kew,et al.  Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[122]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[123]  Hiroyoshi Nishikawa,et al.  Natural and Induced T Regulatory Cells in Cancer , 2013, Front. Immunol..

[124]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[125]  T. Hartung.  Look back in anger - what clinical studies tell us about preclinical work. , 2013, ALTEX.

[126]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[127]  A. Ohta,et al.  The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway , 2012, Front. Immun..

[128]  C. Rosen,et al.  The insulin-like growth factor system in bone: basic and clinical implications. , 2012, Endocrinology and metabolism clinics of North America.

[129]  Torgny Stigbrand,et al.  Radiation-induced cell death mechanisms , 2010, Tumor Biology.

[130]  R. Gorlick,et al.  Development of IGF-IR inhibitors in pediatric sarcomas , 2009, Current oncology reports.

[131]  G. Soukup,et al.  MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes12 , 2009, The Journal of Immunology.

[132]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[133]  L. Helman,et al.  The biology behind mTOR inhibition in sarcoma. , 2007, The oncologist.